1,255 results on '"Brietzke, Elisa"'
Search Results
302. Long Sleep Duration, Insomnia, and Insomnia With Short Objective Sleep Duration Are Independently Associated With Short Telomere Length
303. Hiccups amelioration following a transcranial direct current stimulation protocol targeting central structures
304. Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder
305. Preliminary results from Brazil's first recovery housing program
306. Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review
307. Coronary calcium score as an expression of multisystemic progression of bipolar disorder
308. Effect of male-specific childhood trauma on telomere length
309. Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes
310. Letter to the editor: Inadequate evidence to support improved patient outcomes with combinatorial pharmacogenomics
311. Cognitive impairment in major depressive disorder
312. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression
313. Insights into the Effects of Crack Abuse on the Human Metabolome Using a NMR Approach
314. Predicting antidepressant response using early changes in cognition: A systematic review
315. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments
316. Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design
317. Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?
318. Leptin and adiponectin levels in major depressive disorder: A systematic review and meta-analysis
319. Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders
320. Non-invasive brain stimulation for negative symptoms in schizophrenia: An updated systematic review and meta-analysis
321. Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
322. The impact of body mass index in gene expression of reelin pathway mediators in individuals with schizophrenia and mood disorders: A post-mortem study
323. Mental Disorders, Antidepressants, and Type 2 Diabetes
324. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis
325. Polygenic Risk Score for Alzheimer’s Disease: Implications for Memory Performance and Hippocampal Volumes in Early Life
326. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case–control study
327. Alice in Wonderland syndrome secondary to optical neuromyelitis caused by varicella
328. An immunological age index in bipolar disorder: A confirmatory factor analysis of putative immunosenescence markers and associations with clinical characteristics
329. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
330. Desigualdades no acesso à saúde e suas repercussões no tratamento do transtorno bipolar
331. Non‐Invasive Brain Stimulation for Negative Symptoms in Schizophrenia: An Updated Systematic Review and Meta‐Analysis
332. Targeting cytokines in reduction of depressive symptoms: A comprehensive review
333. Effects of the brain-derived neurotropic factor variant Val66Met on cortical structure in late childhood and early adolescence
334. The differential association between history of childhood sexual abuse and body mass index in early and late stages of bipolar disorder
335. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review
336. Accessing Gene Expression in Treatment-Resistant Schizophrenia
337. Gluten related illnesses and severe mental disorders: a comprehensive review
338. Leukocyte telomere length variation in different stages of schizophrenia
339. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders:A pilot, open-label study
340. Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders
341. Socioeconomic disadvantage moderates the association between peripheral biomarkers and childhood psychopathology
342. Challenges and developments in research of the early stages of bipolar disorder
343. Serum copeptin in children exposed to maltreatment
344. Hippocampus size does not correlate with body mass index in bipolar disorder
345. Coping como função executiva = Coping as executive function = Coping como función ejecutiva
346. Peripheral levels of superoxide dismutase and glutathione peroxidase in youths in ultra-high risk for psychosis: a pilot study
347. A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics
348. Sudden unexpected death in bipolar disorder
349. Treatment with a GLP−1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders
350. Adolescents at clinical-high risk for psychosis: Circadian rhythm disturbances predict worsened prognosis at 1-year follow-up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.